Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Pyme británica ofrece una nueva molécula pequeña para terapia antifibrótica

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20180413001
Publicado:
14/05/2018
Caducidad:
15/05/2019
Resumen:
Una pyme británica ha desarrollado una nueva molécula pequeña que inhibe una vía de señalización celular que desempeña una función en la fibrosis. Esta molécula ha demostrado una potente eficacia y una reducción de los indicadores en un modelo de ratón, y presenta un buen perfil de seguridad tanto en modelos in vitro como in vivo. La empresa busca compañías de la industria farmacéutica especialmente interesadas en la fibrosis para continuar con el desarrollo y comercializar la molécula. El objetivo es establecer acuerdos de licencia o cooperación técnica.

Details

Tittle:
UK-based SME offers novel small molecule anti-fibrotic therapeutic
Summary:
A UK-based SME has developed a novel small molecule that inhibits a cell signalling pathway that has a role in fibrosis. This molecule has shown potent efficacy combined with a good safety profile. The company is offering this molecule to other companies in the pharmaceutical space, especially those interested in fibrosis, for further development and commercialisation. It is envisaged that the partnership will take the form of a licensing agreement or a technical cooperation.
Description:
Certain diseases result in fibrosis of affected tissue. This ´scarring´ causes reduced function compared to healthy tissue, which contributes to disease pathology. Wnt signalling is known to be important for tissue remodelling, such as that seen with fibrosis. Inhibition of the Wnt pathway is therefore likely to help prevent and / or reverse fibrosis in a way more beneficial than standard anti-inflammatory treatment.

A UK-based SME has developed a novel small molecule that inhibits the Wnt signalling pathway. This molecule has been demonstrated to have potent efficacy on the Wnt pathway, shown to reduce indicators of fibrosis in a mouse model and have a good safety profile in both in vitro and in vivo models.

The SME is looking to partner with other companies operating in the pharmaceutical space, especially those with an interest in fibrosis and fibrotic diseases. The SME will provide their novel molecule to a partner for further development and commercialisation. It is envisaged that the partnership will take the form of a licensing agreement or a technical cooperation depending on circumstances.
Advantages and Innovations:
The SME´s novel small molecule has the following advantages:

Potent inhibition of the Wnt pathway - in the nano-molar range in a cell assay system.

Significant reduction of indicators of fibrosis such as connective tissue growth factor, type 1 collagen and fibronectin compared with vehicle controls in a mouse model of kidney fibrosis.

Good safety and pharmacokinetic profiles in in vitro and in vivo models.
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how,Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
The SME is looking to partner with other companies operating in the pharmaceutical sector, especially those with an interest in fibrosis and fibrotic diseases. The SME will offer it´s Wnt signalling pathway inhibitor molecule to partners under licence for the partner for further development, including clinical trials and to take to commercialisation.

It is envisaged that the partnership will take the form of a licensing agreement. Technical cooperations will also be considered dependant on circumstances.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos